Solventum (SOLV) Plans HIS Separation, Is The Stock Still Cheap?
Solventum (SOLV) is in focus after announcing plans to separate its Health Information Systems business, following pressure from activist investor Trian Fund Management, while also reporting Q2 results that exceeded revenue and earnings expectations.
See our latest analysis for Solventum.
Solventum’s restructuring news and Q2 beat come after a strong run in the stock, with a 30 day share price return of 13.35% and a 1 year total shareholder return of 18.11%. This performance suggests momentum has been building as investors reassess both growth prospects and portfolio risk.
If you want to see what else is gaining attention in healthcare technology, this is a good moment to scan 44 healthcare AI stocks.
After a sharp move on the restructuring news, the key issue for Solventum now is whether recent gains already capture the value of a slimmer portfolio and tuck in M&A plans, or if the current valuation still leaves meaningful upside ahead.
Most Popular Narrative: 7.2% Undervalued
Solventum’s most followed narrative pegs fair value at $93.15, a touch above the last close at $86.46, which frames the recent rally in a different light.
Recent commercial restructuring and specialized sales teams are delivering above-expectation growth, especially in core areas like MedSurg and Dental. This indicates that further market penetration and differentiated brand leverage could drive ongoing volume-based revenue increases and support margin expansion.
Want to see what sits behind that fair value for Solventum? The narrative leans heavily on measured revenue growth, slimmer margins, and a higher future earnings multiple. The full set of assumptions may surprise you.
Result: Fair Value of $93.15 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Solventum’s story could shift quickly if the HIS separation or the multi year ERP cutover disrupts operations and weighs on margins or cash flow.
Find out about the key risks to this Solventum narrative.
Next Steps
Opinion on Solventum is clearly split, so this is a good moment to act quickly and stress test the full picture with 3 key rewards and 3 important warning signs.
Looking for more investment ideas beyond Solventum?
If you are serious about building a stronger portfolio, this is the moment to broaden your watchlist with other focused stock ideas sourced from the Simply Wall St screener.
- Target resilience with companies that prioritise capital strength by scanning the solid balance sheet and fundamentals stocks screener (49 results). This can help anchor a portfolio when conditions shift.
- Hunt for mispriced quality and see which opportunities stand out right now by reviewing the 51 high quality undervalued stocks before other investors react.
- Spot potential standouts early by checking the screener containing 18 high quality undiscovered gems before attention and capital crowd into the same familiar stocks.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com